Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Farnesoid X receptor as marker of osteotropism of breast cancers through its role in the osteomimetism of tumor cells

Fig. 3

Treatments performed on MDA-MB-231 cell line: C = control, G = Z-guggulsterone, L = LCA, CDCA = chenodeoxycholic acid. Z: high magnification of a culture exposed to CDCA (Scale bar 30 μm). RUNX2 detection by immunofluorescence after different treatments during 24 h in MDA-MB-231. RUNX2 was evidenced in the nucleus. Z-guggulsterone (g) and LCA (l) caused no variation in RUNX2 expression compared to the control (c). CDCA treatment (CDCA) induced an increase of RUNX2 expression compared to the control (c). Z-guggulsterone or LCA in combined with CDCA (CDCA+G or CDCA+L) induced a decrease in RUNX2 expression compared to CDCA (CDCA). Scale bars = 100 μm. Immunofluorescence image panels of OPN, OC and BSP after equivalent treatments on MDA-MB-231 cell line were illustrated as supplementary Figures 1, 2 and 3. Immunofluorescence image panels of RUNX2, OPN, OC and BSP after equivalent treatments on MCF7 cell line were illustrated as supplementary Figures 4, 5, 6 and 7

Back to article page